Overview
Senthil Selvaraj, MD, MS, MA, is an Assistant Professor of Medicine in the Duke Molecular Physiology Institute and the Division of Cardiology at Duke University Medical Center. Dr. Selvaraj’s translational research explores the therapeutic relevance of cardiovascular metabolism to patients with heart failure. Through early phase work including several clinical trials, his research employs deep phenotyping to decipher metabolic mechanisms that may be leveraged for cardiovascular benefit. These studies characterize dynamic changes in exercise physiology, biomarker profiles integrating multi-omic platforms, echocardiography, arterial stiffness, metabolic molecular imaging techniques, and several other modalities. More recently, this line of inquiry has explored the potential benefits of endogenous and exogenous ketogenic therapies among patients with heart failure. Dr. Selvaraj’s work is currently or recently funded by the National Institutes of Health, American Heart Association, Doris Duke Charitable Foundation, Mandel Foundation, Heart Center Leadership Council, Institute for Translational Medicine and Therapeutics, American Society for Nuclear Cardiology, and Foundation for Sarcoidosis Research.
Current Duke Appointments & Affiliations
Assistant Professor of Medicine
·
2022 - Present
Medicine, Cardiology,
Medicine
Member of Duke Molecular Physiology Institute
·
2022 - Present
Duke Molecular Physiology Institute,
Institutes and Centers
Recent Scholarly Works
Targeted Therapy for ATTR-CM Amidst a Rapidly Evolving Landscape: A Moving Goalpost?
Journal article J Am Coll Cardiol · September 22, 2026 Full text Link to item CiteOvercoming barriers to early diagnosis and treatment of p.Val142Ile amyloid transthyretin (ATTR) cardiomyopathy.
Journal article Heart Fail Rev · July 2, 2026 The most common hereditary transthyretin (ATTRv) amyloidosis variant in the United States, Val122Ile (p.Val142Ile), is predominantly detected in populations of African ancestry. In this narrative review, we highlight the current challenges and discuss prio ... Full text Link to item CiteClinical Outcomes and Health Care Costs in Patients Hospitalized With Heart Failure and Transthyretin Amyloid Cardiomyopathy: Findings From GWTG-HF.
Journal article J Card Fail · July 2026 BACKGROUND: The real-world clinical and economic burden of transthyretin amyloid cardiomyopathy (ATTR-CM) is not well characterized. Prior studies have often been limited by uncertain generalizability or reliance on administrative claims data, which can la ... Full text Link to item CiteRecent Grants
An Open-Label Study to Investigate the Long-Term Effects of Acoramidis on Cardiac Function, Structure and Cardiac Amyloid Burden in Participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Clinical TrialCo Investigator · Awarded by Eidos Therapeutics · 2026 - 2030Metabolic and contractile dysfunction in HFpEF
ResearchCo Investigator · Awarded by National Institutes of Health · 2026 - 2030A phase III, randomized, open-label, blinded endpoint, comparative trial of ferric derisomaltose versus no intravenous iron in irondeficient subjects with symptomatic chronic heart failure
Clinical TrialCo-Principal Investigator · Awarded by Pharmacosmos Therapeutics Inc. · 2026 - 2029View All Grants
Education
University of Pennsylvania, School of Medicine ·
2021
M.S.
Northwestern University, Feinberg School of Medicine ·
2013
M.D.
Northwestern University ·
2012
M.A.
Northwestern University ·
2008
B.A.